Abeona Therapeutics (NASDAQ: ABEO) and Kala Pharmaceuticals (NASDAQ:KALA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.
This table compares Abeona Therapeutics and Kala Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
62.0% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 72.4% of Kala Pharmaceuticals shares are owned by institutional investors. 6.8% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Abeona Therapeutics and Kala Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Abeona Therapeutics||$840,000.00||846.20||-$27.31 million||($0.66)||-22.80|
|Kala Pharmaceuticals||$40,000.00||9,032.56||-$33.16 million||N/A||N/A|
Abeona Therapeutics has higher revenue and earnings than Kala Pharmaceuticals.
This is a summary of recent ratings and recommmendations for Abeona Therapeutics and Kala Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Abeona Therapeutics presently has a consensus price target of $28.50, indicating a potential upside of 89.37%. Kala Pharmaceuticals has a consensus price target of $35.80, indicating a potential upside of 142.96%. Given Kala Pharmaceuticals’ higher probable upside, analysts plainly believe Kala Pharmaceuticals is more favorable than Abeona Therapeutics.
Kala Pharmaceuticals beats Abeona Therapeutics on 6 of the 10 factors compared between the two stocks.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program. The Company has completed two Phase III clinical trials for KPI-121 1% . The KPI-121 0.25% is the Company’s product candidate for temporary relief of signs and symptoms of dry eye disease. KPI-121 1% is the twice-a-day product candidate for treatment of post-operative inflammation and pain following ocular surgery. MPP rTKI Program is therapies for retinal diseases that should be injected directly into the patient’s eye, often at monthly intervals.
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.